ライフサイエンスコーパス: dysphagia

1 (heartburn and/or acid regurgitation and/or dysphagia).

2 stoperative complications (eg, postoperative dysphagia).

3 ild dysphagia) to 4.1 +/- 0.9 (mild/moderate dysphagia).

4 blets for 5 years presented with progressive dysphagia.

5 a trend for improved symptoms, particularly dysphagia.

6 translation in future studies of neurogenic dysphagia.

7 observed association between mast cells and dysphagia.

8 mpared with SWS, especially in patients with dysphagia.

9 roenterology for evaluation of dyspepsia and dysphagia.

10 amel hypoplasia, oral hyperpigmentation, and dysphagia.

11 ocess might contribute to the development of dysphagia.

12 s a differential diagnosis in a patient with dysphagia.

13 ement strategies and outcomes for functional dysphagia.

14 h increased risk for wound complications and dysphagia.

15 l tool for understanding the neural basis of dysphagia.

16 eal stricture who have recurrent symptoms of dysphagia.

17 yopathy, areflexia, respiratory distress and dysphagia.

18 ief, with no differences in GERD symptoms or dysphagia.

19 issen group required intervention for severe dysphagia.

20 r gaze palsy, symmetric motor disability and dysphagia.

21 eakness, areflexia, respiratory distress and dysphagia.

22 a is common among frail elderly persons with dysphagia.

23 combining the frequency and the severity of dysphagia.

24 in the diagnosis and clinical management of dysphagia.

25 opic myotomy can durably relieve symptoms of dysphagia.

26 cation is preferred for patients at risk for dysphagia.

27 ehavioural interventions with usual care for dysphagia.

28 , which resulted in only temporary relief of dysphagia.

29 e a narrowing of the esophagus that leads to dysphagia.

30 eal ring relate ring diameter to presence of dysphagia.

31 14.0-24.0]) were screened for postextubation dysphagia.

32 hagia to be identified, including functional dysphagia.

33 equire reoperation for recurrent GERD and/or dysphagia.

34 llowing pathways as a prelude to therapy for dysphagia.

35 xia (20%), dehydration (16%), diarrhea (8%), dysphagia (10%), esophagitis (20%), fatigue (12%), hyper

36 most frequent grade 3-4 adverse events were dysphagia (17 [27%] of 63 patients in the chemoradiother

37 rm tube feeding-dependency because of severe dysphagia (2 patients) and chronic aspiration (2 patient

38 - 1.5 vs LNF 3.7 +/- 1.6; P = 0.031) but not dysphagia (2.8 +/- 1.9 vs 2.3 +/- 1.7; P = 0.302) and qu

39 in the radiotherapy plus panitumumab group), dysphagia (20 [32%] vs 36 [40%]), and radiation skin inj

40 Distal weakness (26 [41%]), dysphagia (22 [35%]), and dyspnea (23 [37%]) were common

41 e increase was most evident in patients with dysphagia (241 [67%] of 360 patients on STM vs 125 [35%]

42 2.69, 95% CI -2.33 to 7.72, n=231, p=0.293), dysphagia (-3.18, 95% CI -8.36 to 2.00, n=231, p=0.228),

43 In patients with T2D compared to controls, dysphagia (32.3% vs. 13.1%; p = 0.001) and globus sensat

44 [19%]), fatigue (26 [20%] vs 25 [19%]), and dysphagia (35 [27%] vs 37 [29%]).

45 st commonly reported signs and symptoms were dysphagia (53%), dysarthria (39%), and generalized weakn

46 common endoscopy indications in adults were dysphagia (70.1%) and gastroesophageal reflux disease (G

47 or absent) occurred in 74% of patients with dysphagia, 75% with heartburn, 85% with regurgitation, a

48 Common symptoms of EoE included dysphagia (96%), food impaction (74%), and heartburn (94

49 306 patients with clinical dysphagia admitted to hospital with acute stroke were ra

50 axis for reducing pneumonia in patients with dysphagia after acute stroke.

51 Dysphagia after extubation was common in ICU patients, s

52 Dysphagia after mechanical ventilation may be an overloo

53 essment of patients older than 18 years with dysphagia after new stroke recruited from 48 stroke unit

54 on of post-stroke pneumonia in patients with dysphagia after stroke managed in stroke units.

55 Delays in screening for and assessing dysphagia after stroke, are associated with higher risk

56 pital mortality were higher in patients with dysphagia (all p < 0.001).

57 bronchoconstriction, airway mucus secretion, dysphagia, altered gastrointestinal motility, and itchy

58 ted of 221 patients, including 98 (44%) with dysphagia and 123 (56%) with reflux symptoms.

59 included 750 patients of whom 360 (48%) had dysphagia and 390 (52%) had reflux or other symptoms.

60 nts between the ages of 11 and 40 years with dysphagia and active esophageal eosinophilia were random

61 d were recurrent or persistent postoperative dysphagia and an abnormal 24-hour pH test result.

62 However, dysphagia and aspiration remain serious complications, d

63 case series described adults suffering from dysphagia and children with refractory reflux symptoms,

64 ly plays an important role in the genesis of dysphagia and delayed esophageal emptying.

65 ction is an important cause of oropharyngeal dysphagia and distal esophageal symptoms.

66 Dysphagia and dysarthria were the most commonly reported

67 variate HR 2.53; 95% CI 1.69 to 3.78), early dysphagia and early cognitive symptoms.

68 s but has been associated with postoperative dysphagia and esophagitis.

69 ssociated with a low prevalence of new-onset dysphagia and esophagitis.

70 lic esophagitis (EoE) typically present with dysphagia and food impaction.

71 At 1 and 5 years, dysphagia and gas-related symptoms are lower after 180-d

72 e LAF has been alleged to reduce troublesome dysphagia and gas-related symptoms, with similar reflux

73 diaphragmatic pacing, secretions, nutrition, dysphagia and gastrostomy, communication problems, mobil

74 Dysphagia and GERD symptoms are common indications for e

75 Patients with dysphagia and known Barrett's esophagus were excluded.

76 dult-onset disorder characterized by ptosis, dysphagia and proximal limb weakness.

77 Dysphagia and proximal myopathy were common, but urinary

78 Many patients with persistent dysphagia and regurgitation after therapy have low or no

79 One patient had persistent dysphagia and required laser epiglotectomy 108 months af

80 year period, eventually leading to aphonia, dysphagia and severe motor disability with subcortical/f

81 nthetic mesh lowers recurrence but can cause dysphagia and visceral erosions.

82 reased orodental disease, speech impairment, dysphagia, and a significant negative effect on quality

83 % of patients with premature contraction had dysphagia, and all (n = 24; 2.2% overall) were ultimatel

84 progression with disequilibrium, dysarthria, dysphagia, and central hypoventilation, and died 2 month

85 Chest pain, dysphagia, and heartburn scores were not significantly d

86 fects of EVL include hemorrhage, chest pain, dysphagia, and odynophagia.

87 hagia, behavioral adaptations to living with dysphagia, and pain while swallowing accounted for 67% o

88 ostoperative complications, primarily severe dysphagia, and pulmonary complications were more common

89 and these were followed by muscle weakness, dysphagia, and spino-cerebellar signs with impaired gait

90 ephalopathy, with confusion, dysarthria, and dysphagia, and that progresses to severe cogwheel rigidi

91 opy and other symptoms measured by the GSRS, dysphagia, and the Gastrointestinal Quality of Life Inde

92 with an exudative tonsillitis, sore throat, dysphagia, and unilateral neck pain.

93 Clinical characteristics (eg, age, dysphagia, and weight loss) were correlated with LES rel

94 Palifermin appeared to reduce mucositis, dysphagia, and xerostomia during hyperfractionated radio

95 e gender, allergic rhinitis, the presence of dysphagia, and younger age were independently associated

96 ze, slowed horizontal and vertical saccades, dysphagia, apathy, and progressive cognitive decline, wh

97 lonus, hypotonia, optic nerve abnormalities, dysphagia, apnea, and early developmental arrest.

98 Many modalities of palliation of dysphagia are available, but the procedure with least mo

99 Quality of life issues in dysphagia are becoming more widely recognized and recomm

100 g diameters in 332 patients with and without dysphagia are described in a histogram in the original a

101 Although factors such as stroke severity and dysphagia are important predictors of poststroke infecti

102 ed to the pathophysiologic basis of neonatal dysphagia as well as potential opportunities to improve

103 We investigated mechanisms of dysphagia, assessing the response of human esophageal fi

104 ile adjusted OR 1.14, 1.03 to 1.24) and SALT dysphagia assessment (4th quartile adjusted OR 2.01, 1.7

105 auses of mortality after acute stroke, early dysphagia assessment may contribute to preventing deaths

106 n a dose-response manner with delays in SALT dysphagia assessment, with an absolute increase of pneum

107 a screen, and (2) admission to comprehensive dysphagia assessment.

108 gia screen, and 24 542 (39%) a comprehensive dysphagia assessment.

109 edside dysphagia screening and comprehensive dysphagia assessments by a speech and language therapist

110 adiotherapy alone for treatment of malignant dysphagia at 22 hospitals in Australia, Canada, New Zeal

111 not in patients who had a single episode of dysphagia at presentation (P =.229).

112 by gait instability followed by dysarthria, dysphagia, ataxia, or chorea.

113 esthesias and progressed to fever, seizures, dysphagia, autonomic dysfunction, and brain death) was c

114 rapy in 13 (81%) of 16 patients who reported dysphagia before therapy.

115 s that are used to assess characteristics of dysphagia, behavioral adaptations to living with dysphag

116 and women with heartburn and alarm symptoms (dysphagia, bleeding, anemia, weight loss, and recurrent

117 Almost all patients (93%) reported some dysphagia, but dysphagia scores remained significantly l

118 in ring diameter decreased the likelihood of dysphagia by 31%; conversely, a 1-mm decrease in ring di

119 in ring diameter increased the likelihood of dysphagia by 46%.

120 n, stinging pain, foreign body sensation and dysphagia can be observed with this syndrome.

121 Chemoradiotherapy with IMRT aiming to reduce dysphagia can be performed safely for OPC and has high l

122 Dysphagia can result from dysfunction at the mouth, phar

123 umber of ulcers and the subjects' reports of dysphagia, chest pain, and heartburn.

124 uld be considered when patients present with dysphagia, chest pain, and refractory reflux symptoms af

125 measured symptoms (heartburn, regurgitation, dysphagia, chest pain, early satiety, and postprandial p

126 come of the stents as evaluated by recurrent dysphagia, complications and reinterventions.

127 Dysphagia correlated most strongly with overall histopat

128 ve disability, unintelligible speech, severe dysphagia, dependence on wheelchair for mobility, the us

129 New-onset dysphagia developed in only 2 patients.

130 The dysphagia domain correlated most with esophageal gene tr

131 y captures symptoms; (3) determined that the dysphagia domain most closely aligns with symptoms and t

132 is often part of management in patients with dysphagia due to neurological or oropharyngeal disease.

133 autoimmune encephalomyelitis, mice displayed dysphagia due to restriction in jaw and tongue movements

134 quire some type of endoscopic palliation for dysphagia during the course of their illness.

135 of amyotrophic lateral sclerosis--including dysphagia, dysarthria, respiratory distress, pain, and p

136 All patients had relief of dysphagia [dysphagia score </= 1 ("rare")].

137 atio, 1.1:1), ENT symptoms (eg, odynophagia, dysphagia, dysphonia, dyspnea, earache, nasal obstructio

138 suitable for curative treatment, symptomatic dysphagia, Eastern Cooperative Oncology Group performanc

139 opathy, areflexia, respiratory distress, and dysphagia (EMARDD), a rare congenital muscle disease, bu

140 opathy, areflexia, respiratory distress, and dysphagia (EMARDD).

141 This is a very infrequent cause of dysphagia following prone-position ventilation.

142 ve [11%]), and during chemoradiotherapy were dysphagia (four [9%]) and mucositis (four [9%]).

143 A total of 8/30 patients (26.6%) were dysphagia-free after the end of follow-up: 1 (10%) in th

144 Prospective studies have emphasized that dysphagia frequently remains imperfectly diagnosed; some

145 t patients with EAC present with symptoms of dysphagia from late-stage tumors; only a small number of

146 is vital for distinguishing true oesophageal dysphagia from oropharyngeal dysphagia or other causes.

147 technique to 6 patients with severe, chronic dysphagia from stroke (mean of 38.8 +/- 24.4 weeks posts

148 ion in healthy individuals and patients with dysphagia from stroke.

149 a rehabilitative approach for patients with dysphagia from stroke.

150 different clinical symptoms, with increased dysphagia, gagging, cough, and poor appetite compared to

151 However, whether patient-identified domains (dysphagia, gastroesophageal reflux disease [GERD], nause

152 e following terms: heartburn, regurgitation, dysphagia, gastroesophageal reflux disease, cough, aspir

153 ere the following: heartburn, regurgitation, dysphagia, gastroesophageal reflux disease, cough, aspir

154 s in the gastrointestinal tract that include dysphagia, gastroparesis, prolonged gastrointestinal tra

155 a regarding the presence of reflux symptoms, dysphagia, general health, PPI use, and need for surgica

156 tween age groups or sexes, but patients with dysphagia had higher counts (P < .001).

157 The management of oropharyngeal dysphagia has received growing attention recently.

158 linary teams for the effective management of dysphagia have been emphasized by a number of investigat

159 eficiencies in both recognizing and managing dysphagia have been highlighted and recent reviews publi

160 Additionally, risk factors for postoperative dysphagia have been identified, allowing for better pati

161 Such proposed therapies for post-stroke dysphagia have required confirmation of physiological ef

162 Regurgitation improved in 58 (84%) of 69 and dysphagia improved in 27 (82%) of 33.

163 Dysphagia improved or resolved after induction chemother

164 ts with RBES may lead to long-term relief of dysphagia in 30 and 40% of patients, respectively.

165 and symptoms, including dysarthria in 10 and dysphagia in 8 patients, also were observed among our LE

166 the most suitable therapy for palliation of dysphagia in a given patient.

167 ing but not restricted to food impaction and dysphagia in adults, and feeding intolerance and GERD sy

168 5 and 2015 on various modes of palliation of dysphagia in carcinoma esophagus were studied, which wer

169 The prevalence of dysphagia in critical illness polyneuropathy is not know

170 this study was to evaluate the prevalence of dysphagia in critical illness polyneuropathy using fiber

171 contributing factors for the development of dysphagia in critical illness polyneuropathy.

172 iques for quantifying the type and degree of dysphagia in patients are described.

173 rescribed for palliative relief of malignant dysphagia in patients with incurable oesophageal cancer.

174 The increased odds of postoperative dysphagia in the group undergoing myotomy with anterior

175 e and well tolerated treatment for malignant dysphagia in the palliative setting.

176 or achalasia, it may also lead to persistent dysphagia in these patients with esophageal aperistalsis

177 The most frequent adverse event was dysphagia (in 68% of patients postoperatively, in 11% at

178 The dysphagia incidence at ICU discharge was 10.3% (n = 96/9

179 monias, venous thromboembolism, fever, pain, dysphagia, incontinence, and depression are particularly

180 with stroke experience swallowing problems (dysphagia); increased risk of aspiration pneumonia, maln

181 Dysphagia is a common symptom in the general population.

182 Oesophageal dysphagia is a so-called red flag alarm symptom requirin

183 The onset of dysphagia is associated with advanced disease, which has

184 Coexistent dysphagia is considered an alarm symptom, prompting eval

185 Dysphagia is frequent among patients with critical illne

186 Achalasia should be considered when dysphagia is present and not explained by an obstruction

187 Dysphagia is well known to deteriorate outcome in the IC

188 We investigated the incidence of dysphagia, its time course, and association with clinica

189 eviewers have identified shortcomings in the dysphagia knowledge base and have stressed the need for

190 egree partial fundoplication, offset by less dysphagia, leading to a clinical outcome that is equival

191 yond standard toxicity end points, physician dysphagia logs (PDLs), daily patient swallowing diaries,

192 ogressive limb weakness, muscle atrophy, and dysphagia, making them vulnerable to insufficient energy

193 involved and the results of developments in dysphagia management are published in a range of journal

194 Dysphagia may develop in or after the fourth decade of l

195 esophagitis, heartburn score, dilatation for dysphagia, modified Dakkak dysphagia score (0-45), and r

196 gurgitation in 5 patients (46%), followed by dysphagia (n = 4, 37%) and chest pain (n = 2, 18%).

197 dity, mortality, and long-term palliation of dysphagia needs to be chosen for the patient.

198 Based on evidence from the post-stroke dysphagia neurostimulation literature, these changes may

199 y healthy female presented with intermittent dysphagia, odynophagia and loss of weight of 3 months du

200 (4% versus 4%) and 8 weeks (11% versus 9%), dysphagia/odynophagia/chest pain (9% versus 2%), strictu

201 weakness, wasting, spasticity, dysarthria or dysphagia of one central nervous system region defined a

202 iting (one), diarrhoea (one), fatigue (one), dysphagia (one), neck pain (one), and diaphoresis (one);

203 ars of age or older, choking or pill-induced dysphagia or globus caused 37.6% (95% CI, 29.1 to 46.2)

204 ; adjusted OR, 1.67; 95% CI, 1.10- 2.53) and dysphagia or hoarseness (4.35% with BMP vs 2.45% without

205 rue oesophageal dysphagia from oropharyngeal dysphagia or other causes.

206 ignificantly more likely to have symptoms of dysphagia (OR=10.67; p=0.03) and reduced forced vital ca

207 Neonatal dysphagia, or abnormalities of swallowing, represent a m

208 ntraindications to antibiotics, pre-existing dysphagia, or known infections, or who were not expected

209 skin reaction, pneumonitis, dyspnea, cough, dysphagia, or neutropenia.

210 of mild hoarseness, with no associated pain, dysphagia, or stridor.

211 ymptomatic group and patients with recurrent dysphagia (P <.001) but not in patients who had a single

212 elated to specific parent-reported symptoms: dysphagia (P = .0012), GERD (P = .0001), and nausea/vomi

213 elaxation in mean age (P = .59), duration of dysphagia (P = .18), or weight loss (P > .99).

214 ts with intracerebral haemorrhage (p=0.014), dysphagia (p=0.003) and urinary incontinence/catheterisa

215 so showed benefits for docetaxel in reducing dysphagia (p=0.02) and abdominal pain (p=0.01).

216 eks later), and key secondary endpoints were dysphagia progression-free survival (defined as a worsen

217 iotherapy alone, with minimal improvement in dysphagia progression-free survival and overall survival

218 Median dysphagia progression-free survival was 4.1 months (95%

219 eactivity was predictive for muscle atrophy, dysphagia, pronounced muscle fiber damage, and vasculiti

220 t presents in the fifth or sixth decade with dysphagia, ptosis and proximal limb weakness.

221 y presents in the fifth or sixth decade with dysphagia, ptosis and proximal limb weakness.

222 ssociated with pain (r = 0.27, P = .06) than dysphagia (r = 0.24, P = .13).

223 In patients with chronic dysphagia, real PAS induced short-term bilateral changes

224 Dysphagia, recurrence and need for redo fundoplication w

225 hat screening patients with acute stroke for dysphagia reduces the risk of stroke-associated pneumoni

226 perative demographics and symptom scores for dysphagia, regurgitation, and chest pain.

227 ingested food not only leads to symptoms of dysphagia, regurgitation, chest pain, and weight loss, b

228 2 = moderate; 3 = severe) symptom severity (dysphagia, regurgitation, heartburn, chest pain) preoper

229 ation," "any re-operation/re-intervention," "dysphagia/regurgitation," and "micronutrient status." Th

230 ndividuals and has therapeutic potential for dysphagia rehabilitation.

231 interaction (HCI) for swallowing training in dysphagia rehabilitation.

232 The primary endpoint was dysphagia relief (defined as >/=1 point reduction on the

233 %, 26-44) in the radiotherapy group obtained dysphagia relief (difference 10.6%, 95% CI -2 to 23; p=0

234 ition, 170 (85%) patients achieved excellent dysphagia relief (responders).

235 1.3, making more likely to achieve excellent dysphagia relief after myotomy compared with those with

236 t not statistically significant, increase in dysphagia relief compared with radiotherapy alone, with

237 hemoradiotherapy with radiotherapy alone for dysphagia relief in the palliative setting.

238 At a mean follow-up of 11.4 months, dysphagia relief persisted for all patients.

239 All patients had dysphagia relief, 83% having relief of noncardiac chest

240 -term follow-up, showed excellent results on dysphagia relief.

241 verity and length of mechanical ventilation, dysphagia remained an independent predictor for 28-day a

242 However, severe dysphagia requiring endoscopy +/- dilatation was signifi

243 Symptoms (weight loss, dysphagia, retrosternal pain, and regurgitation) were as

244 All patients had relief of dysphagia [dysphagia score </= 1 ("rare")].

245 e, dilatation for dysphagia, modified Dakkak dysphagia score (0-45), and reoperation rate.

246 Patients were stratified by hospital, dysphagia score (Mellow scale 1-4), and presence of meta

247 At 1 year, the Dakkak dysphagia score [2.8 vs 4.8; weighted mean difference: -

248 ean follow-up of 42.1 months, the mean delta dysphagia score was 7.1 +/- 2.6; therefore, the myotomy

249 ophageal sphincter pressure or postoperative dysphagia score was observed.

250 At 5 years, the Dakkak dysphagia score, flatulence, inability to belch, and ina

251 tudy was the postoperative change (delta) in dysphagia score.

252 Mean dysphagia scores improved from 3.3 (SD 0.6) pre-SEMS (n=

253 tients in the wrap group did not have higher dysphagia scores or lower heartburn scores than the no w

254 patients (93%) reported some dysphagia, but dysphagia scores remained significantly lower than preop

255 Dysphagia scores, morbidity, mortality, and survival wer

256 fundoplication, which was reflected by lower dysphagia scores.

257 ures were time from (1) admission to bedside dysphagia screen, and (2) admission to comprehensive dys

258 mitted with acute stroke, 55 838 (88%) had a dysphagia screen, and 24 542 (39%) a comprehensive dysph

259 Patients with the longest delays in dysphagia screening (4th quartile adjusted OR 1.14, 1.03

260 We aimed to identify if delays in bedside dysphagia screening and comprehensive dysphagia assessme

261 spective observational trial with systematic dysphagia screening and follow-up until 90 days or death

262 Dysphagia screening was positive in 12.4% (n = 116/933)

263 ain scan within 12 h, brain scan within 1 h, dysphagia screening), a day of the week pattern (stroke

264 d 8 of the 13 QIs for performance reporting: dysphagia screening, National Institutes of Health Strok

265 dystonia, chorea, parkinsonism, dysarthria, dysphagia, seizures, cognitive abnormalities, and acanth

266 ration, risk of fatigue, sexual dysfunction, dysphagia, shortness of breath and/or hypotension, proce

267 with AS (ataxia, action tremor, dysarthria, dysphagia, sialorrhea and excessive chewing/mouthing beh

268 -quarter of patients developed postoperative dysphagia similarly distributed between both groups.

269 Thirteen patients (93%) had dysphagia, six (43%) had food impactions, and six (43%)

270 presents commonly in adults as long standing dysphagia, sometimes with food impaction.

271 essive choreoathetoid movements, dysarthria, dysphagia, spastic paralysis, and behavioral dementia in

272 ity (EPX) were significantly associated with dysphagia (strongest r = 0.37, P = .02).

273 Co-primary outcomes were change in Dysphagia Symptom Questionnaire (DSQ) score from baselin

274 nly one phenotype of a broader 'inflammatory dysphagia syndrome' spectrum.

275 h handwriting, but later falls, rigidity and dysphagia than PSP.

276 Interestingly, dysphagia, the main symptom of adult EoE patients follow

277 ation to allow the causes of non-obstructive dysphagia to be identified, including functional dysphag

278 e of 1 to 7) worsened from 2.9 +/- 1.5 (mild dysphagia) to 4.1 +/- 0.9 (mild/moderate dysphagia).

279 Both patients exhibited dysarthria, dysphagia, tongue atrophy, neck extensor weakness, and w

280 nonsmoker volunteers and 7 patients with UES dysphagia using a concurrent manometric and video endosc

281 ariate hazard ratio for 90-day mortality for dysphagia was 3.74 (95% CI, 2.01-6.95; p < 0.001).

282 At 1 year after therapy, observer-rated dysphagia was absent or minimal (scores 0 to 1) in all p

283 Persistent postoperative dysphagia was defined as 1 standard deviation less than

284 Dysphagia was diagnosed in 6 and mild voice abnormalitie

285 d with their wild-type littermates; however, dysphagia was not apparent.

286 Bedside screening for dysphagia was performed within 3 hours after extubation

287 Dysphagia was significantly less common after surgery (p

288 The incidence of postoperative dysphagia was similar in the 2 groups, however, signific

289 l and psychological symptoms including pain, dysphagia, weight loss, disfigurement, depression, and x

290 Alarm features such as dysphagia, weight loss, or anemia raise concern of an up

291 The odds of postoperative dysphagia were 0.06 (95% CI, 0.03-0.12) for myotomy only

292 onstrated therapeutic promise in post-stroke dysphagia when applied contralaterally.

293 y can safely and durably relieve symptoms of dysphagia while also reducing symptoms of reflux.

294 lower reintervention rates for postoperative dysphagia, while providing similar reflux control compar

295 ination of severe parkinsonism, near mutism, dysphagia with choking, vertical supranuclear gaze palsy

296 or chemotherapy for long-term palliation of dysphagia with good quality of life.

297 o discuss the recent trends in palliation of dysphagia with promising results and the most suitable t

298 al swallowing neurophysiology in post-stroke dysphagia with therapeutic effects which are critically

299 ublingual lisinopril, or placebo if they had dysphagia, within 36 h of symptom onset in this double-b

300 All measures of dysphagia worsened soon after therapy; observer-rated an